Acute Leukemia of Ambiguous Lineage — Trials

Acute Leukemia of Ambiguous Lineage — Trials · CancerIndex

Clinical trials

Registered studies

139 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 65
Recruiting: 38
Ph III recruiting: 2
Growth YoY: —
Industry share: 14%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (20)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07498465	A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia	withdrawn	Phase 1	0	Children's Oncology GroupNETWORK	0	May 5, 2026	clinicaltrials
NCT05170828	Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	withdrawn	Phase 1	0	Ossium Health, Inc.INDUSTRY	0	Feb 24, 2026